Compare UMH & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMH | QURE |
|---|---|---|
| Founded | 1968 | 1998 |
| Country | United States | Netherlands |
| Employees | 540 | 248 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | UMH | QURE |
|---|---|---|
| Price | $15.31 | $26.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $17.75 | ★ $45.00 |
| AVG Volume (30 Days) | 683.9K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $5.51 | $126.12 |
| Revenue Next Year | $2.51 | $200.43 |
| P/E Ratio | $203.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.93 | $8.73 |
| 52 Week High | $17.44 | $71.50 |
| Indicator | UMH | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 55.52 |
| Support Level | $14.74 | $23.06 |
| Resistance Level | $15.56 | $29.03 |
| Average True Range (ATR) | 0.30 | 1.84 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 57.58 | 38.29 |
UMH Properties Inc together with its subsidiaries, is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents. The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, it sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for its sites and homes, where the company is the lessor.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.